Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease  by Herrington, David M et al.
Endothelial Function
Individual and Combined Effects of
Estrogen/Progestin Therapy and Lovastatin on Lipids
and Flow-Mediated Vasodilation in Postmenopausal
Women With Coronary Artery Disease
David M. Herrington, MD, MHS, FACC,* Brian L. Werbel, MD,* Ward A. Riley, PHD,†
Benjamin E. Pusser, BA,* Timothy M. Morgan, PHD‡
Winston-Salem, North Carolina
OBJECTIVES We sought to examine the individual and combined effects of estrogen/progestin therapy versus
lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with heart disease.
BACKGROUND Little information is available regarding the relative benefits of estrogen replacement therapy
versus reductase inhibitors and the potential utility of their combination as lipid-lowering
therapy for postmenopausal women.
METHODS We conducted a randomized, double-blind, crossover trial in 24 postmenopausal women,
each of whom received the following drug regimens during three consecutive six-week
treatment periods: 1) hormone replacement (oral dose of 0.625 mg/day conjugated equine
estrogens and 2.5 mg/day medroxyprogesterone acetate); 2) 20 mg lovastatin/day and 3)
hormone replacement plus lovastatin.
RESULTS Total and low density lipoprotein (LDL) cholesterol were significantly lowered and high
density lipoprotein (HDL) cholesterol was significantly increased by all three regimens
compared with baseline (p , 0.05). Lovastatin was more effective than estrogen/progestin in
reducing LDL (p , 0.001), but estrogen/progestin was slightly more effective in increasing
HDL. The hormone replacement and lovastatin regimen blocked the estrogen-associated increase
in triglycerides. Hormone replacement (alone and with lovastatin) resulted in increases in brachial
artery flow-mediated vasodilator capacity (p 5 0.01 for both regimens) and the area under the
curve (p 5 0.016 and p 5 0.005, respectively) compared with baseline. Percent dilation was
greatest after the hormone replacement regimen, whereas the area under the curve was greatest
after hormone replacement plus lovastatin (69% improvement vs. baseline).
CONCLUSIONS In postmenopausal women with coronary disease and hyperlipidemia, conjugated equine
estrogen produced significant improvements in lipids and vasodilator responses despite the
concurrent administration of low dose medroxyprogesterone acetate. Low dose lovastatin
produced greater reductions in LDL, but less dramatic improvements in vasodilator
responses. Estrogen/progestin plus lovastatin may provide additional benefits via a greater
reduction in the LDL/HDL ratio and attenuation of estrogen-associated hypertriglyceride-
mia. More information is needed about the safety and efficacy of such combinations of
hormone replacement and reductase inhibitor therapy. (J Am Coll Cardiol 1999;33:2030–7)
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An expanding body of epidemiologic and mechanistic data
suggests that estrogen may be uniquely efficacious for
prevention of cardiovascular disease in postmenopausal
women (1–3). On the basis of these observations, several
expert and consensus panels recommend estrogen replace-
ment for primary and secondary prevention of coronary
disease (4–6). The National Cholesterol Education Pro-
gram Adult Treatment Panel II Guidelines state that “in
postmenopausal women who qualify for drug therapy for
LDL lowering, estrogen replacement therapy can be con-
sidered as an alternative to [other LDL lowering] drugs”
(5). However, the recently reported Heart and Estrogen/
Progestin Replacement Study failed to confirm a reduction
in risk for myocardial infarction and cardiovascular death in
women with coronary disease given estrogen plus progestin
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for 4.1 years (7). This result raises questions about the role
of estrogen replacement versus conventional lipid-lowering
therapy for secondary prevention of heart disease in women,
especially because two mechanisms through which estrogen
was thought to prevent clinical cardiovascular events—lipid
lowering (8) and improved endothelial function (9,10)—are
also the presumed mechanisms of action for 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase inhib-
itor therapy (11,12).
One possible explanation of the Heart and Estrogen/
Progestin Replacement Study results is that the medroxy-
progesterone acetate (MPA) used attenuated the beneficial
effects of estrogen on lipids and endothelial function. To
address these questions, we present data from a randomized,
double-blind, crossover trial examining the individual and
combined effects of estrogen plus MPA and lovastatin on
plasma lipids and brachial artery flow-mediated vasodilator
responses in postmenopausal women with coronary disease
and elevated low density lipoprotein (LDL) cholesterol
concentrations.
METHODS
Postmenopausal women admitted to the North Carolina
Baptist Hospital from June 1, 1994 to December 31, 1995
were screened for eligibility. Objective evidence of coronary
disease and a fasting plasma LDL cholesterol .3.36 mmol/
liter were required. Established coronary disease included
prior myocardial infarction, prior coronary revascularization
procedure or coronary angiography revealing at least one
vessel with $30% stenosis. We defined postmenopausal as:
1) .55 years and no natural menses for at least 5 years; 2)
follicle-stimulating hormone .40 MIU/ml and no natural
menses for at least 1 year; 3) documented oophorectomy or
4) self-reported oophorectomy, follicle-stimulating hor-
mone .40 MIU/ml and estradiol ,25 pg/ml. Women were
excluded if they were .80 years of age, current users of
estrogen replacement or lipid-lowering therapy, or known
or suspected to have a current contraindication for estrogen
therapy (i.e., breast or endometrial carcinoma, history of
deep venous thrombophlebitis or pulmonary embolus,
symptomatic gallstone disease, fasting triglycerides .4.5
mmol/liter or active liver disease with serum glutamic-
oxaloacetic transaminase .1.5). Women were also ineligible
if they were diabetic and required either insulin or oral
agents, were taking high dose or multidrug antihypertensive
regimens or had a known allergy to HMG-CoA reductase
therapy. The protocol was approved by the Clinical Re-
search Practices Committee at our institution, and each
woman gave written consent. A total of 24 women (average
age: 66.8 6 6.6 years) were enrolled. Two women dropped
out before their final treatment period because of concerns
raised by the death of their sister due to breast cancer. A
third woman dropped out after the first treatment period
because of intolerable breast tenderness and ankle edema.
Each woman served as her own control by receiving three
drug regimens in random order during three consecutive
six-week treatment periods. The regimens were as follows:
1) estrogen/progestin (oral conjugated equine estrogen
0.625 mg plus MPA 2.5 mg daily) and lovastatin placebo; 2)
estrogen/progestin placebo and lovastatin 20 mg daily and
3) estrogen/progestin plus lovastatin therapy. The clinic staff
and participants were blinded to treatment assignment.
Fasting plasma lipids and brachial artery flow-mediated
vasodilator capacity were measured at baseline and after
each six-week treatment period.
Nitrates, calcium channel blocking agents, angiotensin-
converting enzyme inhibitors and persantine were discon-
tinued for 24 h before the brachial artery test. All women
rested quietly in a supine position for a minimum of 15 min
before the test began. A standard pediatric cuff was placed 2
in. (5.08 cm) below the right antecubital fossa. Blood
pressure and heart rate were monitored at 5-min intervals
throughout the procedure using an automated sphygmoma-
nometer on the left arm. The brachial artery was identified
approximately 7 cm proximal to the brachial bifurcation
using a 10-MHz Biosound Phase 2 (Indianapolis, Indiana)
ultrasound system. A midsagittal imaging plane was con-
firmed by the simultaneous viewing of both the blood–
intimal and medial–adventitial interfaces on the near and far
walls. Once the transducer position was established, baseline
images were obtained for 2 min. After baseline imaging, the
blood pressure cuff was inflated to 50 mm Hg above systolic
blood pressure and maintained for 3 min. The brachial
artery was continuously imaged for the 3 min of cuff
occlusion and for 2 min immediately after cuff release.
Image analysis was done in the Wake Forest University
Cardiology Image Processing Laboratory by a technician
who was blinded to the treatment assignments. After
identifying the portion of the tape demonstrating the
brachial artery at baseline, frames were automatically digi-
tized into 640 3 480 3 8 bit grey scale images every 300 ms
during the first minute of the baseline period for a total of
30 frames (10 s) and stored on the image analysis computer
(Sun Microsystems, Palo Alto, California). Using an auto-
mated boundary detection algorithm developed in our
laboratory (13), the medial–adventitial boundary on the near
and far wall of the brachial artery were located over an
arterial segment 2.0 to 2.5 cm in length. In the first frame,
the boundary detection algorithm used a dynamic program-
ming strategy to seek the best set of spatially continuous
edge points consistent with the near and far wall medial–
adventitial boundaries. If a boundary point was obviously
Abbreviations and Acronyms
AUC 5 area under the diameter curve
HDL 5 high density lipoprotein
HMG-CoA 5 3-hydroxy-3-methylglutaryl coenzyme A
LDL 5 low density lipoprotein
MPA 5 medroxyprogesterone acetate
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displaced from the true medial–adventitial boundary, the
technician manually edited the boundary point in question
and the automated detection algorithm was rerun. Once the
boundaries were established, vessel diameter was estimated
by averaging the perpendicular distance from near to far wall
through each pixel of the centerline of the vessel. Using
boundary locations in the first frame as a starting point, the
software automatically identified the boundaries of interest
and raw diameters for all 30 baseline frames. The resulting
diameter versus time curve was smoothed with a nine-point
(frame) sliding weighted average producing an estimate of
the mean arterial diameter at each point during the baseline
recording. The mean diameter of the artery at baseline was
then defined as the average of the smoothed diameters from
the 30 baseline frames.
A similar procedure was used to automatically determine
the continuous estimate of mean arterial diameter during
the 2 min after cuff release. The automated method was
used to measure the diameter in all 360 frames, and the
sliding weighted average was used to determine the estimate
of mean arterial diameter at any time after cuff release. The
resulting diameter estimates were plotted against time (Fig.
1). The primary measure of analysis was relative change in
mean arterial diameter, calculated as follows: percent dila-
tion 5 [(maximum diameter 2 baseline diameter)/(baseline
diameter)] 3 100, where maximum diameter 5 the largest
mean arterial diameter observed during the 2 min after cuff
deflation. The area under the diameter curve (AUC),
measured as mmzs, was also calculated as the time integral of
the difference between the postcuff diameter, during the
2-min dilation phase, and the diameter established at
baseline.
Continuous surveillance of the mean brachial artery
diameter during dilation has been shown to be a more
reliable measure of the maximal vasodilator response than
single or multiple measurements at discrete time points after
the flow stimulus (14). To establish the variability of this
technique, 88 subjects enrolled in a separate study were
examined twice on different days at baseline and twice after
a dietary intervention. The coefficient of variation of max-
imum/baseline based on the full nested analysis of variance
model was 2.10%, comparable to previously published
reproducibility data (15,16).
Total plasma cholesterol and triglycerides were measured
on the Technicon RA-100 analyzer using enzymatic meth-
ods, as described in the Technicon RA Systems Methods
Manual (Gaithersburg, Maryland) for cholesterol (SM4-
0139D91) and for triglycerides glycerol phosphate oxidase
with glycerol blank correction (SM4-0207E92). Coeffi-
cients of variation are ,1% for total cholesterol and ,2%
for triglycerides and high density lipoprotein (HDL) cho-
lesterol. High density lipoprotein cholesterol was measured
by the heparin–manganese precipitation method (17) as
detailed in the Manual of Laboratory Operations of the
Lipid Research Clinics Program (18). Low density lipopro-
tein cholesterol was calculated using the Friedewald equa-
tion (19).
Statistical analysis. The study was designed as a random-
ized order crossover trial. Sample size calculations before the
study indicated that, assuming a correlation of 0.82, the
study had 80% power to detect a 10% treatment effect on
vasodilator responses at the 5% level of significance with 24
subjects. The SAS (Cary, North Carolina) procedure
PROC MIXED (20) was used to model the repeated
measures while adjusting for missing data on the three
women with incomplete follow-up. The general linear
model was parameterized (21) to estimate the effects of
Figure 1. Plot of brachial artery diameter at baseline and 2 min after release of the blood pressure cuff. The maximum diameter observed
over 2 min was used to calculate the vasodilator response. AUC 5 area under the diameter curve.
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treatment on lipid concentrations and brachial artery mea-
sures. Tests for treatment order effects were not significant
at the 0.05 level for all outcomes except LDL/HDL ratio
(p 5 0.01). Adjustments for order effects resulted in minor
quantitative, but no qualitative, differences in the results. All
results are reported unadjusted for order except where
indicated in the text.
RESULTS
Current (n 5 4, 16.7%) or ever (n 5 12, 50%) smoking, and
history of hypertension (n 5 15, 62.5%) were present in
more than 50% of the patients. Eight women (33%) had had
a myocardial infarction, 8 had undergone a coronary artery
bypass graft procedure and 5 (20%) had undergone percu-
taneous transluminal coronary angiography. In three sub-
jects, the diagnosis of coronary disease was based exclusively
on the presence of angiographically defined disease that had
not yet required revascularization or caused a myocardial
infarction. Aspirin (n 5 16, 67%) and calcium channel
blockers (n 5 10, 42%) were the most common cardiovas-
cular medications taken. Six women (25%) took nitrates,
five (21%) took beta-adrenergic blocking agents, two (8%)
took angiotensin-converting enzyme inhibitors and one
(4%) took persantine.
Lipids. Total and LDL cholesterol were significantly low-
ered and HDL cholesterol was significantly elevated by
lovastatin, estrogen/progestin and their combination when
compared with baseline (p , 0.05; Fig. 2, Table 1). The
LDL/HDL ratio was also significantly improved by each
treatment regimen (p , 0.05). Lovastatin was more effective
at lowering total cholesterol, LDL and LDL/HDL ratio
than estrogen/progestin (p , 0.05 for all three compari-
sons). Estrogen/progestin resulted in slightly greater im-
provement in HDL levels than lovastatin (15% vs. 10%, p 5
0.32). Estrogen/progestin plus lovastatin resulted in the
greatest reduction in total cholesterol and LDL (21% and
33%, respectively) and the greatest increase in HDL (17%).
The LDL/HDL ratio with estrogen/progestin plus lova-
statin was 43% lower than baseline (p , 0.0001). This result
was better than that achieved with estrogen/progestin
alone (p , 0.001) or lovastatin alone (p 5 0.04; after
adjustment for order effect, p 5 0.08). An unexpected
finding was that estrogen/progestin plus lovastatin abol-
ished the estrogen-associated increase in triglycerides
(Fig. 2) (p , 0.001).
Brachial artery flow-mediated dilation. Analysis of bra-
chial diameter before cuff occlusion revealed no significant
treatment effects on resting diameter (p 5 0.11). Estrogen/
progestin alone and with lovastatin resulted in 45% to 69%
increases in percent dilation (p 5 0.01 for each) and AUC
(p 5 0.016 and p 5 0.005, respectively) compared with
baseline (Table 1). Lovastatin alone resulted in a 29%
increase in percent dilation and a 32% increase in AUC
(p 5 0.07 and p 5 0.08, respectively). None of the three
treatment groups was statistically different from another for
either measure of vasodilator response. Percent dilation was
Figure 2. Plot of mean (SE) lipid levels at baseline and at the end of each treatment period. Numbers at the top of each bar are the percent
change from baseline. Both 5 HMG plus HRT; HDL 5 high density lipoprotein; HMG 5 lovastatin; HRT 5 conjugated equine
estrogen and medroxyprogesterone acetate; LDL 5 low density lipoprotein. P values for all pair-wise comparisons are found in Table 1.
*p , 0.05 vs. baseline.
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greatest after the estrogen replacement regimen, whereas
the AUC was greatest after estrogen/progestin plus lova-
statin therapy (69% improvement compared with baseline).
Correlations between lipids and endothelial function.
To estimate the extent to which improvements in endothe-
lial function could be accounted for by changes in plasma
lipids, the Pearson correlation coefficients for average
change in plasma lipids during the three treatment periods
versus the average change in vasodilator responses were
calculated. Changes in LDL and LDL/HDL ratio were
negatively correlated with AUC (LDL, R 5 20.46, p 5
0.05; LDL/HDL ratio, R 5 20.37, p 5 0.09). Correlations
between change in HDL and vasodilator responses were all
,0.1 (p 5 NS). When the observations were examined
individually, similar trends were observed, but none of the
correlation coefficients reached statistical significance.
DISCUSSION
This study quantifies the beneficial effects of estrogen plus
MPA therapy, lovastatin and their combination on plasma
lipids and brachial artery flow-mediated vasodilator re-
sponses in postmenopausal women with established coro-
nary artery disease and elevated LDL cholesterol. The
estrogen regimen produced significant increases in HDL
cholesterol and vasodilator capacity, even with continuous
low dose MPA. Lovastatin produced greater reductions in
LDL cholesterol and lesser improvements in HDL choles-
terol and vasodilator responses. Estrogen/progestin plus
lovastatin yielded greater reductions in the LDL/HDL ratio
than either therapy alone. Finally, estrogen/progestin plus
lovastatin blocked the modest increase in triglycerides asso-
ciated with estrogen/progestin replacement.
Effects of estrogen on lipids and endothelial function.
Several clinical trials have examined the effects of estrogen
replacement regimens on plasma lipids and lipoproteins in
postmenopausal women with normal plasma lipids (8,22–
26). These studies have documented 6% to 28% reductions
in LDL cholesterol and 2% to 19% increases in HDL with
unopposed estrogen therapy. The addition of MPA has
generally resulted in smaller increases in HDL (8,24,27),
whereas other, more androgenic, progestins have resulted in
no change (24) or even reductions (26) in HDL cholesterol.
Four clinical trials have examined the lipid effects of
estrogen replacement in postmenopausal women with hy-
percholesterolemia (28–31). The two studies of unopposed
estrogen (29,30) reported 13.5% to 27% reductions in LDL
cholesterol and 21% to 24% increases in HDL cholesterol.
In a study by Darling et al. (31), 1.25 mg estrogen plus
5.0 mg continuous progestin resulted in a 24% reduction in
LDL cholesterol, whereas HDL cholesterol increased by
7%. In the current study, 0.625 mg conjugated estrogen plus
2.5 mg continuous MPA resulted in a 15% reduction in
LDL cholesterol, a 15% increase in HDL cholesterol and a
26% reduction in LDL/HDL ratio after six weeks of
treatment.
There is ample in vitro (32,33) evidence that estrogen
replacement has a fundamentally important effect on
endothelium-dependent vasodilation. In vivo studies in
surgically postmenopausal nonhuman primates and post-
menopausal women also have shown that both acute
(10,34–36) and chronic (9,37) administration of estrogen
can enhance coronary vasodilator responses to acetylcholine.
Similar effects of estrogen have been documented in the
brachial artery in response to either acetylcholine (38,39) or
increased blood flow (40–42).
Studies in cynomolgus monkeys (43) suggest that MPA
may offset estrogen’s potential benefits on endothelium-
dependent vasodilation. But studies in women provide no
evidence that adding a progestin significantly changes bra-
chial flow-mediated dilation (42,44). A recent study using
transdermal estradiol and vaginal micronized progesterone
also found no attenuation of estrogen’s effects on brachial
artery dilation (40). The present study further documents
Table 1. Mean (SE) Lipid Values and Vasodilator Response at Baseline and After Each Treatment Period
Baseline HMG HRT Both
p Values for Pair-Wise
Treatment Comparisons
HMG vs.
HRT
HMG vs.
Both
HRT vs.
Both
Lipids (mmol/L)
TC 6.44 (0.15) 5.20 (0.21)* 6.07 (0.21)† 5.12 (0.21)* ,0.001 0.50 ,0.001
LDL-C 4.21 (0.13) 2.95 (0.21)* 3.60 (0.18)* 2.84 (0.18)* ,0.001 0.30 ,0.001
HDL-C 1.10 (0.05) 1.21 (0.06)† 1.26 (0.06)* 1.29 (0.06)* 0.31 0.12 0.39
TG 2.46 (0.18) 2.25 (0.24) 2.69 (0.22) 2.22 (0.19) 0.004 0.85 ,0.001
LDL/HDL 3.99 (0.18) 2.58 (0.20)† 2.94 (0.18)† 2.29 (0.18)* 0.02 0.04‡ ,0.001
Vasodilator responses
% dilation 3.5 (0.4) 4.5 (0.5)§ 5.7 (0.7)† 5.1 (0.7)† 0.11 0.33 0.59
AUC 24.0 (3.1) 31.6 (3.8)\ 39.2 (4.6)† 41.0 (7.1)† 0.11 0.12 0.84
*Versus baseline, p , 0.001. †Versus baseline, p , 0.05. ‡After adjustment for order effect, p 5 0.08. §Versus baseline, p 5 0.07. \Versus baseline, p 5 0.08.
AUC 5 area under the curve; C 5 cholesterol; HDL 5 high density lipoprotein; HMG 5 lovastatin; HRT 5 conjugated equine estrogen plus medroxyprogesterone acetate;
LDL 5 low density lipoprotein; TC 5 total cholesterol; TG 5 triglycerides.
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that significant improvements in response to an endothelial-
directed vasodilator stimulus are possible using a commonly
prescribed regimen of oral estrogen combined with low
dose, continuous MPA.
Effects of reductase inhibitors on lipids and endothelial
function. The effects of lovastatin on lipids in the current
study are comparable to previously published results in
women with hypercholesterolemia. In a study of women
taking lovastatin 20 mg/day (45) (the same dose used in the
current study), LDL cholesterol was reduced by 24.4%, and
HDL cholesterol increased 6.7%. Davidson et al. (29)
observed a 25.4% reduction in LDL cholesterol and a 3.7%
increase in HDL cholesterol in postmenopausal women
with hypercholesterolemia who took pravastatin 20 mg/day
for 16 weeks. Darling et al. (31) reported a 36% decrease in
LDL cholesterol and a 7% increase in HDL cholesterol in
hypercholesterolemic women who took simvastatin 10 mg
daily for eight weeks. Clinical trials of lipid lowering in men
and women with and without coronary disease have also
demonstrated improvements in coronary (11,12,46,47) and
brachial (48) endothelial function.
Combined effects of hormone replacement and lovastatin
on lipids and endothelial function. There are few data
available concerning the combination of estrogen replace-
ment and lipid-lowering therapy. Bradford et al. (45)
reported more favorable lipid profiles in women taking
estrogen and lovastatin than lovastatin alone. Espeland et al.
(49) made similar observations in a secondary analysis of
lipid data from the Asymptomatic Carotid Artery Progres-
sion Study. However, estrogen use was not randomized in
these trials, and the details about type and dose of estrogen
and the use of concomitant progestins are not available. In
the only previously published randomized trial of estrogen
replacement and lipid-lowering therapy in humans, estrogen
plus pravastatin 20 mg resulted in greater reductions in
LDL and greater elevations in HDL than pravastatin alone
(29). The combined effect on LDL/HDL ratio in that study
was remarkably similar to our findings (241.4% vs.
247.6%, respectively).
In the current study, lovastatin eliminated the modest
increase in triglycerides associated with estrogen plus pro-
gestin therapy. The effects of lovastatin on the larger, and
potentially more important, increase in triglycerides associ-
ated with unopposed estrogen are unknown. Because estro-
gen raises triglycerides by promoting the production of large
very low density lipoprotein particles, which are preferen-
tially taken up by the liver rather than being converted to
LDL (22), estrogen-associated hypertriglyceridemia may be
less atherogenic than other triglyceride disorders. Because
triglyceride levels are independently associated with risk for
heart disease in women (50), and estrogen-induced triglyc-
eride elevations are also associated with smaller, more
atherogenic LDL particles (30,51), a strategy for minimiz-
ing estrogen-induced hypertriglyceridemia may still be very
important for the prevention of heart disease in postmeno-
pausal women.
Mechanisms for improvement in flow-mediated vasodi-
lator responses. Oxidized LDL can down-regulate or de-
stabilize nitric oxide synthase (52) and enhance production
of free oxygen radicals that inactivate nitric oxide (53,54).
These mechanisms could, in part, account for the adverse
effects of hypercholesterolemia as well as the benefits of
lipid-lowering therapy with reductase inhibitors or estrogen
on endothelial nitric oxide–mediated vasodilation. How-
ever, the improved endothelial function associated with
reductase inhibitors or estrogen therapy may stem from
other direct vascular effects. Studies in nonhuman primates
(34) and humans (35,55) suggest that estrogen can result in
rapid (within 20 min) improvements in endothelial function
independent of its lipid effects, and pravastatin also exerts
beneficial, lipid-independent effects on endothelial function
in nonhuman primates (56). The modest correlations be-
tween changes in lipids and changes in endothelial function
in the present study provide further evidence that estrogen
replacement (and possibly lovastatin) have favorable, lipid-
independent effects on endothelial function. Such improve-
ments in endothelial function may help mitigate against
vasoconstrictor stimuli that potentially initiate or complicate
acute ischemic syndromes (57,58) and enhance the ability to
inhibit inflammatory responses (59), platelet aggregation
(60) and thrombosis (61).
Limitations of the study. The magnitude of the brachial
artery vasodilator responses we observed is smaller than
those reported by others (15,39,62). This may be explained
by the older age of the study cohort, and the fact that all
subjects had hypercholesterolemia and established coronary
disease. We used a 3-min period of cuff occlusion. However,
a recent study of healthy postmenopausal women using a
4-min cuff occlusion reported vasodilator responses that
were similar in magnitude to ours (44). Concerns about the
womens’ willingness to repeatedly undergo the procedure
lead us not to administer nitroglycerin as a positive control.
However, because each woman served as her own control,
the improved vasodilator responses after treatment verified
that the impaired responses at baseline were not due to a
fixed, intrinsic inability to dilate.
Conclusions. These data provide estimates of the lipid-
and flow-mediated vasodilator effects of estrogen/progestin
therapy and lovastatin in women eligible for cholesterol-
lowering therapy. Substantial improvements were realized
with estrogen replacement despite concomitant low dose,
continuous MPA. This study also provides evidence that the
greatest improvements in LDL/HDL ratio and triglycerides
may be realized by combining estrogen replacement and
lovastatin. Our data suggest that any discordance between
HMG-CoA reductase inhibitors and estrogen replacement
for secondary prevention of cardiovascular events cannot be
attributed to major differences in their effects on lipids or
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vasodilator capacity. More data on the effects and safety of
other hormone replacement regimens with and without
higher doses of lovastatin or more potent reductase inhibi-
tors are needed.
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